查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1572200

BREO Ellipta 製藥市場：按疾病、成分、最終用戶、分銷管道分類 - 2025-2030 年全球預測

BREO Ellipta Drugs Market by Disease Condition (Asthma, COPD), Component (Corticosteroid (ICS), Long-Acting Beta2-Adrenergic Agonist), End User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

BREO Ellipta 製藥市場 2023 年估值為 30.5 億美元，預計到 2024 年將達到 31.8 億美元，複合年成長率為 4.53%，到 2030 年將達到 41.6 億美元。

BREO Ellipta 藥物市場主要用於治療慢性阻塞性肺病(COPD) 和氣喘，這是由人口老化加劇、呼吸系統疾病盛行率上升以及早期診斷和治療意識不斷提高所推動的。這些藥物是Fluticasone和Vilanterol的聯合治療，旨在改善肺功能並減少病情加重。對 BREO Ellipta 藥物的需求源於對有效、易於使用、長效呼吸治療的需求不斷成長。主要用途是用於慢性阻塞性肺病和氣喘的症狀管理，最終用途集中在醫院、診所和居家醫療機構。促進該市場成長的主要因素包括給藥系統的技術進步、支持性的政府法規以及越來越容易患呼吸道疾病的老年人口。最近的潛在商機在於利用遠端醫療來擴大兒科醫學和遠端患者監護的應用。向醫療需求未被滿足的新興市場擴張也帶來了新的商機。然而，市場面臨一些限制因素，例如治療成本高、皮質類固醇相關的副作用以及學名藥的競爭，這些可能會抑製成長。此外，嚴格的法規環境和臨床試驗要求延長了上市時間。創新和研發領域包括提高聯合治療的功效、開發以患者為中心的吸入器以及整合數位健康技術以提高依從性和結果。了解生物相似藥領域、投資於降低製造成本的策略以及收購本地企業可以進一步提高您的市場佔有率。 BREO Ellipta 市場是一個適度細分且競爭激烈的市場，重點放在研發活動上，以在不斷發展的製藥領域保持競爭力。透過監控監管趨勢並建立強大的分銷網路，公司可以最佳化其市場地位並利用現有的成長機會實現顯著成長。

主要市場統計
基準年[2023] 30.5億美元
預測年份 [2024] 31.8億美元
預測年份 [2030] 41.6億美元
複合年成長率（%） 4.53%

市場動態：揭示快速發展的 BREO Ellipta 製藥市場的關鍵市場洞察

BREO Ellipta 供需的動態交互作用正在改變藥品市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性呼吸道疾病盛行率上升
    • 增強的吸入器技術可提高劑量準確性和患者舒適度
    • 改善新興市場的醫療保健基礎設施和藥品的獲取
  • 市場限制因素
    • 副作用和長期安全問題
  • 市場機會
    • 透過與醫療機構建立夥伴關係，建立醫療保健專業人員對 Breo Ellipta 的信任
    • 開發包括 Breo Ellipta 在內的聯合治療，以提高患者的依從性
  • 市場挑戰
    • 複雜的法規環境因國家而異

波特五力：駕馭 BREO Ellipta 藥品市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 BREO Ellipta 製藥市場的外部影響

外部宏觀環境因素在塑造 BREO Ellipta 製藥市場的業績動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解 BREO Ellipta 藥品市場的競爭狀況

對 BREO Ellipta 製藥市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 BREO Ellipta 供應商製藥市場績效評估

FPNV 定位矩陣是評估 BREO Ellipta Pharmaceuticals 市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製 BREO Ellipta 藥品市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對 BREO Ellipta Pharmaceuticals 市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性呼吸道疾病盛行率上升
      • 吸入器技術的增強提高了劑量準確性和患者舒適度
      • 改善新興市場的醫療保健基礎設施和藥品的獲取
    • 抑制因素
      • 副作用和長期安全問題
    • 機會
      • 與醫療機構建立夥伴關係並培養醫療工作者對 BREO Ellipta 的信任
      • 開發包括 BREO Ellipta 在內的聯合治療，以提高患者的依從性
    • 任務
      • 不同國家的法規環境變得更加複雜和多樣化。
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第 6 章 BREO Ellipta 藥品市場（依疾病狀況）

  • 氣喘
  • 慢性阻塞性肺病

第 7 章 BREO Ellipta 製藥市場：按組成部分

  • 皮質類固醇 (ICS)
  • 長效BETA2腎上腺素促效劑

第 8 章 BREO Ellipta 製藥市場：依最終用戶分類

  • 診所
  • 家庭護理設置
  • 醫院

第 9 章 BREO Ellipta 製藥市場：按分銷管道

  • 網上銷售
  • 藥局

第10章 BREO Ellipta美洲製藥市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 BREO Ellipta 亞太地區藥品市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲的 BREO Ellipta 製藥市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Iconovo 吸入式 GLP-1 受體促效劑的開發選擇
    • FDA 將氣喘藥物 Breo Ellipta 的核准擴大到 5 至 17 歲兒童
  • 戰略分析和建議
Product Code: MRR-81515600A1FD

The BREO Ellipta Drugs Market was valued at USD 3.05 billion in 2023, expected to reach USD 3.18 billion in 2024, and is projected to grow at a CAGR of 4.53%, to USD 4.16 billion by 2030.

The market for BREO Ellipta drugs, utilized primarily in treating chronic obstructive pulmonary disease (COPD) and asthma, is driven by a growing aging population, rising prevalence of respiratory ailments, and heightened awareness regarding early diagnosis and treatment. These medications provide a combination therapy approach of fluticasone and vilanterol, aimed at improving lung function and reducing exacerbations. The necessity for BREO Ellipta drugs stems from the increasing demand for effective, easy-to-use, and long-acting respiratory treatments. The major applications include symptom management in COPD and asthma, whereas end-use is concentrated in hospitals, clinics, and homecare settings. Key factors contributing to the growth of this market include technological advancements in drug delivery systems, supportive government regulations, and an expanding geriatric population more susceptible to respiratory diseases. Recent potential opportunities lie in extending application to pediatric care and exploiting telemedicine for remote patient monitoring. Expansion into emerging markets with unmet medical needs presents another opportunity. However, the market faces limiting factors, such as high treatment costs, side effects associated with corticosteroids, and competition from generic drug alternatives, which may restrain growth. Additionally, stringent regulatory environments and the essential requirement for clinical trials prolong market entry timelines. Areas for innovation and research prominently involve enhancing the efficacy of combination therapies, developing patient-centric inhalers, and integrating digital health technologies to improve compliance and outcomes. Understanding the biosimilars landscape, investing in strategies to reduce production costs, and acquisitions of local players can further bolster market presence. The nature of the BREO Ellipta market is moderately fragmented and competitive, emphasizing research and development activities to maintain a competitive edge in the ever-evolving pharmaceuticals landscape. By navigating regulatory pathways and building robust distribution networks, businesses can optimize their market position and leverage existing opportunities for substantial growth.

KEY MARKET STATISTICS
Base Year [2023] USD 3.05 billion
Estimated Year [2024] USD 3.18 billion
Forecast Year [2030] USD 4.16 billion
CAGR (%) 4.53%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving BREO Ellipta Drugs Market

The BREO Ellipta Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic respiratory diseases
    • Enhancements in inhaler technology to improve dosing accuracy and patient comfort
    • Improving healthcare infrastructure and access to medications in emerging markets
  • Market Restraints
    • Adverse side effects and long-term safety concerns
  • Market Opportunities
    • Developing partnerships with healthcare organizations to foster trust in BREO Ellipta among healthcare providers
    • Development of combination therapies involving BREO ellipta for enhanced patient compliance
  • Market Challenges
    • Complex and varying regulatory environments across different countries

Porter's Five Forces: A Strategic Tool for Navigating the BREO Ellipta Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the BREO Ellipta Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the BREO Ellipta Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the BREO Ellipta Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the BREO Ellipta Drugs Market

A detailed market share analysis in the BREO Ellipta Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the BREO Ellipta Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the BREO Ellipta Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the BREO Ellipta Drugs Market

A strategic analysis of the BREO Ellipta Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the BREO Ellipta Drugs Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Cipla Limited, GlaxoSmithKline plc, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, Orion Corporation, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the BREO Ellipta Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Condition, market is studied across Asthma and COPD.
  • Based on Component, market is studied across Corticosteroid (ICS) and Long-Acting Beta2-Adrenergic Agonist.
  • Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals.
  • Based on Distribution Channel, market is studied across Online Sales and Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic respiratory diseases
      • 5.1.1.2. Enhancements in inhaler technology to improve dosing accuracy and patient comfort
      • 5.1.1.3. Improving healthcare infrastructure and access to medications in emerging markets
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse side effects and long-term safety concerns
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing partnerships with healthcare organizations to foster trust in BREO Ellipta among healthcare providers
      • 5.1.3.2. Development of combination therapies involving BREO ellipta for enhanced patient compliance
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and varying regulatory environments across different countries
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. BREO Ellipta Drugs Market, by Disease Condition

  • 6.1. Introduction
  • 6.2. Asthma
  • 6.3. COPD

7. BREO Ellipta Drugs Market, by Component

  • 7.1. Introduction
  • 7.2. Corticosteroid (ICS)
  • 7.3. Long-Acting Beta2-Adrenergic Agonist

8. BREO Ellipta Drugs Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals

9. BREO Ellipta Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Online Sales
  • 9.3. Pharmacies

10. Americas BREO Ellipta Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific BREO Ellipta Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa BREO Ellipta Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Iconovo's development of inhaled GLP-1 receptor agonists options
    • 13.3.2. FDA expands Breo Ellipta approval to children aged 5-17 for asthma maintenance
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca plc
  • 2. Boehringer Ingelheim International GmbH
  • 3. CHIESI Farmaceutici S.p.A.
  • 4. Cipla Limited
  • 5. GlaxoSmithKline plc
  • 6. Hikma Pharmaceuticals PLC
  • 7. Lupin Pharmaceuticals, Inc.
  • 8. Merck & Co., Inc.
  • 9. Novartis AG
  • 10. Orion Corporation
  • 11. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. BREO ELLIPTA DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BREO ELLIPTA DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BREO ELLIPTA DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BREO ELLIPTA DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY CORTICOSTEROID (ICS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY LONG-ACTING BETA2-ADRENERGIC AGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BREO ELLIPTA DRUGS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES BREO ELLIPTA DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM BREO ELLIPTA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. BREO ELLIPTA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. BREO ELLIPTA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023